Tigecycline Hepatotoxicity and Dosing in Moderate Hepatic Impairment
No dose adjustment is required for patients with moderate hepatic impairment (Child-Pugh B) receiving tigecycline—maintain the standard 100 mg loading dose followed by 50 mg every 12 hours. 1
Dose Adjustment by Hepatic Function
The FDA labeling provides clear guidance stratified by Child-Pugh classification:
- Child-Pugh A (mild): No adjustment needed—standard dosing (100 mg load, then 50 mg q12h) 1
- Child-Pugh B (moderate): No adjustment needed—standard dosing (100 mg load, then 50 mg q12h) 1
- Child-Pugh C (severe): Reduce maintenance dose to 25 mg q12h after 100 mg loading dose, with close monitoring 1
Hepatotoxicity Risk Profile
Tigecycline carries a 5.7-23% incidence of drug-induced liver injury (DILI), which exceeds the "frequent" threshold (>5%) defined by regulatory standards 2, 3. The hepatotoxicity pattern is predominantly:
- Cholestatic (75%): Most common presentation with slower recovery (41.5% recovery rate) 2
- Hepatocellular (18%): Better recovery profile (70% recovery rate) 2
- Mixed (7%): Intermediate recovery (50% recovery rate) 2
Independent Risk Factors for Hepatotoxicity
Multiple studies identify consistent predictors requiring heightened vigilance:
Dose-Related Factors:
- High maintenance dose (100 mg q12h vs. 50 mg q12h): OR 1.028 per mg increase 2
- Prolonged duration (>14 days): OR 1.208 per day, with 100% of DILI cases receiving >14 days 2
- Cumulative dose: OR 1.51 per gram, with median DILI onset at 4 days 3
Drug Exposure Thresholds:
- Trough concentration (Cmin) >0.535 mg/L predicts hepatotoxicity 4
- Concentration at 6 hours (C6h) >0.690 mg/L predicts hepatotoxicity 4
- AUC0-24 elevation correlates with increased risk 4
Concomitant Medications:
- Voriconazole co-administration: significantly increases risk 4
- Statins: significantly increases risk 4
- Multiple hepatotoxic drugs: OR 2.232 per additional agent 2
Pharmacokinetic Considerations in Hepatic Impairment
In moderate hepatic impairment (Child-Pugh B), tigecycline clearance is reduced but not to the extent requiring dose adjustment 5, 6. Real-world data demonstrate:
- Patients with Child-Pugh B achieve adequate PK/PD targets (AUC0-24/MIC ≥4.5 for pulmonary infections) with standard dosing 5
- For intra-abdominal infections requiring AUC0-24/MIC ≥6.96, >80% achieve targets when MIC ≤1 mg/L 5
In severe hepatic impairment (Child-Pugh C), tigecycline exposure increases substantially, necessitating dose reduction to prevent toxicity 1, 5. The MELD score significantly influences clearance and can guide individualized dosing 7.
Monitoring Strategy
Baseline Assessment:
- Liver function tests (AST, ALT, bilirubin, alkaline phosphatase)
- Child-Pugh classification
- Review all concomitant hepatotoxic medications
- Consider baseline fibrinogen (risk of hypofibrinogenemia, especially Child-Pugh C) 5
During Therapy:
- Monitor liver enzymes every 2-3 days initially, then twice weekly
- Median DILI onset is 4 days, but Kaplan-Meier analysis shows continued risk through 18 days 3
- If therapeutic drug monitoring available, maintain Cmin <0.535 mg/L and C6h <0.690 mg/L 4
- Monitor fibrinogen in Child-Pugh C patients (100% developed hypofibrinogenemia in one study) 5
Clinical Guideline Context
Guidelines note that tigecycline should be used cautiously in patients with liver insufficiency 8. While tigecycline-based regimens show inferior outcomes compared to aminoglycosides for complicated UTIs and may be inferior to polymyxins for bloodstream infections caused by carbapenem-resistant Enterobacteriaceae 9, when used for appropriate indications (particularly pneumonia with high-dose regimens), hepatic monitoring becomes paramount.
Critical Pitfalls to Avoid
- Do not empirically reduce dose in Child-Pugh B—this risks treatment failure without reducing hepatotoxicity risk 1
- Avoid prolonged courses (>14 days) when possible—100% of DILI cases in one study exceeded 14 days 2
- Discontinue or substitute voriconazole and statins when feasible during tigecycline therapy 4
- Do not use standard dosing in Child-Pugh C—this population requires 50% maintenance dose reduction 1
- Early monitoring is essential—median DILI onset is 4 days, not weeks 3